{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:33:33Z","timestamp":1715945613014},"reference-count":34,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009430","name":"Baxter BioScience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009430","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Immunoglobulins (Igs) have been in clinical use for almost 70 years, and early on were also used in conjunction with exposure to the measles virus or polio virus. The US regulations that describe functional Ig lot release thus require the demonstration of minimum antibody titers against these two viruses, although the use of vaccines has now dramatically reduced their incidence. The lower clinical importance of these viruses raises the question of whether other virus antibodies might be more informative for patients with immunodeficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>A literature survey was conducted to identify viruses of potential clinical concern for people with immunodeficiency. The viruses selected have stable seroepidemiology and associated functional antibody assays. As a result, neutralizing antibody titers to human adenovirus 5 (HAdV5), respiratory syncytial virus (RSV) serotypes A and B, and human parainfluenza virus 3 (hPIV3) were determined in Ig lots produced from plasma collected in either the United States or the European Union.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The virus antibody titers measured were high and consistent among the Ig lots tested. Use of either US\u2010 or EU\u2010derived plasma as starting material resulted in equivalent virus antibody titers, with the exception of RSV serotype B, for which a lower titer was seen in EU plasma\u2013derived Ig lots.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>With the significant decline in measles virus and polio virus circulation, and even their potential eradication, measurement of antibody titers against other viruses in Ig products may be more informative for functional lot release testing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.15016","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T14:18:50Z","timestamp":1544192330000},"page":"3090-3095","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunoglobulins and virus antibody titers: of past needs, current requirements, and future options"],"prefix":"10.1111","volume":"58","author":[{"given":"Thomas R.","family":"Kreil","sequence":"first","affiliation":[{"name":"Global Pathogen Safety, Shire (previously Baxter BioScience, Baxalta)  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R.","family":"Farcet","sequence":"additional","affiliation":[{"name":"Global Pathogen Safety, Shire (previously Baxter BioScience, Baxalta)  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_2_7_3_1","unstructured":"WHO model list of essential medicines; 20th list; 2017. [cited 2018 Jun 30]. Available fromhttp:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/20th_EML2017.pdf?ua=1"},{"key":"e_1_2_7_4_1","unstructured":"US Food and Drug Administration. Code of federal regulations title 21 part 640 subpart J section 640.104: additional standards for human blood and blood products immune globulin (human) potency; 2017 [cited 2018 Jun 30]. Available fromhttps:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=640.104"},{"key":"e_1_2_7_5_1","unstructured":"WHO global action plan to minimize poliovirus facility\u2010associated risk after type\u2010specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use WHO\/POLIO\/15.05. 2015 [cited 2018 Jun 30]. Available fromhttp:\/\/polioeradication.org\/wp-content\/uploads\/2016\/12\/GAPIII_2014.pdf"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/506363"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.008"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix428"},{"key":"e_1_2_7_9_1","unstructured":"CDC West Nile virus statistics and maps [cited 2018 Jun 30]. Available fromhttps:\/\/www.cdc.gov\/westnile\/statsmaps\/index.html"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/519392"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1510.081668"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02155-10"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05705-11"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2807\/ese.16.10.19812-en"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13953"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(99)00008-X"},{"key":"e_1_2_7_17_1","unstructured":"BoyleMImmune deficiency foundation 2016 PPTA regulatory workshop June 13 2016 [cited 2018 Jun 30]. Available fromhttps:\/\/www.pptaglobal.org\/images\/Regulatory_Workshop\/2016_Presentations\/1d_Marcia_Boyle_Patient_Advocate_Perspective.pdf."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.07.018"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6639a2"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40011-011-0008-7"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2002.1066"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.4.9807067"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03209.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702656"},{"key":"e_1_2_7_25_1","first-page":"191","volume-title":"Water recreation and disease. Plausibility of associated infections: acute effects, sequelae and mortality","author":"World Health Organization (WHO)","year":"2006"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21980"},{"key":"e_1_2_7_27_1","first-page":"515","article-title":"Enterovirus and parechovirus surveillance \u2013 United States, 2014\u20132016","volume":"67","author":"Abedi GR","year":"2018","journal-title":"MMWR"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12246"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2017.03.005"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113563"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.145"},{"key":"e_1_2_7_32_1","volume-title":"Medical microbiology","author":"Baron S","year":"1996"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piu047"},{"key":"e_1_2_7_34_1","unstructured":"CDC Human Parainfluenza Viruses (hPIVs) clinical overview [cited 2018 Jun 30]. Available fromhttps:\/\/www.cdc.gov\/parainfluenza\/hcp\/clinical.html"},{"key":"e_1_2_7_35_1","unstructured":"WHO health topics essential medicines [cited 2018 Jun 30]. Available fromhttp:\/\/www.who.int\/topics\/essential_medicines\/en\/"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.15016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.15016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:34:12Z","timestamp":1694630052000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.15016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/trf.15016"],"URL":"https:\/\/doi.org\/10.1111\/trf.15016","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"2018-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}